Mantle cell lymphoma

Journal of Clinical Oncology

Volumn 34, Issue 11, 2016, Pages 1256-1269

  Cheah, Chan Yoon ^a,b,e   Seymour, John F ^c,d   Wang, Michael L ^e  

^a SIR CHARLES GAIRDNER HOSPITAL   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BENDAMUSTINE; BORTEZOMIB; CYTARABINE; IBRUTINIB; LENALIDOMIDE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE; RITUXIMAB; THALIDOMIDE;

CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER TRANSPLANTATION; CLINICAL FEATURE; DRUG CHOICE; HUMAN; INDUCTION CHEMOTHERAPY; MAINTENANCE CHEMOTHERAPY; MANTLE CELL LYMPHOMA; MANTLE CELL LYMPHOMA INTERNATIONAL PROGNOSTIC INDEX; MOLECULAR PATHOLOGY; MOLECULARLY TARGETED THERAPY; MULTICENTER STUDY (TOPIC); PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; STEM CELL TRANSPLANTATION; TIME TO TREATMENT; TREATMENT OUTCOME; ANALOGS AND DERIVATIVES; AUTOTRANSPLANTATION; DRUG ADMINISTRATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; LYMPHOMA, MANTLE-CELL; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; RISK FACTOR;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENDAMUSTINE HYDROCHLORIDE; BORTEZOMIB; CYTARABINE; DRUG ADMINISTRATION SCHEDULE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; INDUCTION CHEMOTHERAPY; LYMPHOMA, MANTLE-CELL; MAINTENANCE CHEMOTHERAPY; MOLECULAR TARGETED THERAPY; NEOPLASM STAGING; PROGNOSIS; PYRAZOLES; PYRIMIDINES; RISK FACTORS; RITUXIMAB; THALIDOMIDE; TRANSPLANTATION, AUTOLOGOUS;

EID: 84962445099     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2015.63.5904     Document Type: Review

References (143)

1. Swerdlow SHCE, Campo E, Harris N, et al: WHO Classification of Tumours of the Haematopoeitic and Lymphoid Tissues (ed 4). Lyon, France, International Agency for Research on Cancer, 2008
2. Zhou Y, Wang H, Fang W, et al: Incidence trends of mantle cell lymphoma in the United States between 1992 and 2004. Cancer 113:791-798, 2008
3. Gallagher CJ, Gregory WM, Jones AE, et al: Follicular lymphoma: Prognostic factors for response and survival. J Clin Oncol 4:1470-1480, 1986
4. Barista I, Romaguera JE, Cabanillas F: Mantlecell lymphoma. Lancet Oncol 2:141-148, 2001
5. Jares P, Colomer D, Campo E: Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 122:3416-3423, 2012
6. Sherr CJ: G1 phase progression: Cycling on cue. Cell 79:551-555, 1994
7. Aggarwal P, Vaites LP, Kim JK, et al: Nuclear cyclin D1/CDK4 kinase regulates CUL4 expression and triggers neoplastic growth via activation of the PRMT5 methyltransferase. Cancer Cell 18:329-340, 2010
8. Bienvenu F, Jirawatnotai S, Elias JE, et al: Transcriptional role of cyclin D1 in development revealed by a genetic-proteomic screen. Nature 463: 374-378, 2010
9. Meggendorfer M, Kern W, Haferlach C, et al: SOX11 overexpression is a specific marker for mantle cell lymphoma and correlates with t(11;14) translocation, CCND1 expression and an adverse prognosis. Leukemia 27:2388-2391, 2013
10. Nordström L, Sernbo S, Eden P, et al: SOX11 and TP53 add prognostic information to MIPI in a homogenously treated cohort of mantle cell lymphoma-a Nordic Lymphoma Group study. Br J Haematol 166:98-108, 2014
11. Navarro A, Clot G, Royo C, et al: Molecular subsets of mantle cell lymphoma defined by the IGHV mutational status and SOX11 expression have distinct biologic and clinical features. Cancer Res 72: 5307-5316, 2012
12. Mozos A, Royo C, Hartmann E, et al: SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype. Haematologica 94:1555-1562, 2009
13. Vegliante MC, Palomero J, Pé rez-Galán P, et al: SOX11 regulates PAX5 expression and blocks terminal B-cell differentiation in aggressive mantle cell lymphoma. Blood 121:2175-2185, 2013
14. Palomero J, Vegliante MC, Rodríguez ML, et al: SOX11 promotes tumor angiogenesis through transcriptional regulation of PDGFA in mantle cell lymphoma. Blood 124:2235-2247, 2014
15. Rosenwald A, Wright G, Wiestner A, et al: The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. Cancer Cell 3: 185-197, 2003
16. Katzenberger T, Petzoldt C, Hö ller S, et al: The Ki67 proliferation index is a quantitative indicator of clinical risk in mantle cell lymphoma. Blood 107:3407, 2006
17. Hoster E, Rosenwald A, Berger F, et al: Tumor cell proliferation (Ki-67 index) overcomes cytology and growth pattern as prognostic factor inmantle-cell lymphoma-results from randomized trials of the European MCL Network. Blood 124:2014 (abstr 2977)
18. Zhang J, Jima D, Moffitt AB, et al: The genomic landscape of mantle cell lymphoma is related to the epigenetically determined chromatin state of normal B cells. Blood 123:2988-2996, 2014 (abstr)
19. Beà S, Valdé s-Mas R, Navarro A, et al: Landscape of somatic mutations and clonal evolution in mantle cell lymphoma. Proc Natl Acad Sci U S A 110: 18250-18255, 2013
20. Balasubramanian S, Schaffer M, Deraedt W, et al: Mutational analysis of patients with primary resistance to single-agent ibrutinib in relapsed or refractory mantle cell lymphoma (MCL). Presented at the ASH Annual Meeting and Exposition, San Francisco, CA, December 6-9, 2014
21. Chiron D, Di Liberto M, Martin P, et al: Cellcycle reprogramming for PI3K inhibition overrides a relapse-specific C481S BTK mutation revealed by longitudinal functional genomics in mantle cell lymphoma. Cancer Discov 4:1022-1035, 2014
22. Kridel R, Meissner B, Rogic S, et al: Whole transcriptome sequencing reveals recurrent NOTCH1 mutations in mantle cell lymphoma. Blood 119:1963-1971, 2012
23. Burger JA, Ford RJ: The microenvironment in mantle cell lymphoma: Cellular and molecular pathways and emerging targeted therapies. Semin Cancer Biol 21:308-312, 2011
24. Kurtova AV, Tamayo AT, Ford RJ, et al: Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): Importance for interactions with the stromal microenvironment and specific targeting. Blood 113:4604-4613, 2009
25. Zhang L, Yang J, Qian J, et al: Role of the microenvironment inmantle cell lymphoma: IL-6 is an important survival factor for the tumor cells. Blood 120:3783-3792, 2012
26. Yang ZZ, Novak AJ, Stenson MJ, et al: Intratumoral CD4+CD25+ regulatory T-cell-mediated suppression of infiltrating CD4+ T cells in B-cell non-Hodgkin lymphoma. Blood 107:3639-3646, 2006
27. Argatoff LH, Connors JM, Klasa RJ, et al: Mantle cell lymphoma: A clinicopathologic study of 80 cases. Blood 89:2067-2078, 1997
28. Pittaluga S, Wlodarska I, Stul MS, et al: Mantle cell lymphoma: A clinicopathological study of 55 cases. Histopathology 26:17-24, 1995
29. Sánchez-Aguilera A,Montalbán C, De La Cueva P, et al: Spanish Hodgkin Lymphoma Study Group: Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 108:662-668, 2006
30. Kiaii S, Clear AJ, Ramsay AG, et al: Follicular lymphoma cells induce changes in T-cell gene expression and function: Potential impact on survival and risk of transformation. J Clin Oncol 31: 2654-2661, 2013
31. Wang L, Qian J, Lu Y, et al: Immune evasion of mantle cell lymphoma: Expression of B7-H1 leads to inhibited T-cell response to and killing of tumor cells. Haematologica 98:1458-1466, 2013
32. Fu K, Weisenburger DD, Greiner TC, et al: Lymphoma/Leukemia Molecular Profiling Project: Cyclin D1-negative mantle cell lymphoma: A clinicopathologic study based on gene expression profiling. Blood 106:4315-4321, 2005
33. Gesk S, Klapper W, Martín-Subero JI, et al: A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 108:1109-1110, 2006
34. Cheson BD, Fisher RI, Barrington SF, et al: Alliance, Australasian Leukaemia and Lymphoma Group; Eastern Cooperative Oncology Group; European Mantle Cell Lymphoma Consortium; Italian Lymphoma Foundation; European Organisation for Research; Treatment of Cancer/Dutch Hemato-Oncology Group; Grupo Español De Mé dula Ó sea; German High-Grade Lymphoma Study Group; German Hodgkin's Study Group; Japanese Lymphorra Study Group; Lymphoma Study Association; NCIC Clinical Trials Group; Nordic Lymphoma Study Group; Southwest Oncology Group; United Kingdom National Cancer Research Institute: Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: The Lugano classification. J Clin Oncol 32:3059-3068, 2014
35. Abrahamsson A, Albertsson-Lindblad A, Brown PN, et al: Real world data on primary treatment for mantle cell lymphoma: A Nordic Lymphoma Group observational study. Blood 124:1288-1295, 2014
36. Romaguera JE, Medeiros LJ, Hagemeister FB, et al: Frequency of gastrointestinal involvement and its clinical significance in mantle cell lymphoma. Cancer 97:586-591, 2003
37. Cheah CY, George A, Giné E, et al: European Mantle Cell Lymphoma Network: Central nervous system involvement in mantle cell lymphoma: Clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol 24:2119-2123, 2013
38. Chihara D, Asano N, Ohmachi K, et al: Ki-67 is a strong predictor of central nervous system relapse in patients with mantle cell lymphoma (MCL). Ann Oncol 26:966-973, 2015
39. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 329:987-994, 1993
40. Hoster E, Dreyling M, Klapper W, et al: German Low Grade Lymphoma Study Group (GLSG); European Mantle Cell Lymphoma Network: A new prognostic index (MIPI) for patients with advancedstage mantle cell lymphoma. Blood 111:558-565, 2008
41. Hoster E, Rosenwald A, Berger F, et al: Prognostic value of proliferation, cytology, and growth pattern in mantle cell lymphoma: Results from randomized trials of the European MCL Network. Hematol Oncol 33:129, 2015
42. Delfau-Larue M-H, Klapper W, Berger F, et al: CDKN2A and TP53 deletions predict adverse outcome in younger mantle cell lymphoma patients, independent of treatment and MIPI. Presented at the ASH Annual Meeting and Exposition, Orlando, FL, December 5-8, 2015
43. Ferǹandez V, Salamero O, Espinet B, et al: Genomic and gene expression profiling defines indolent forms of mantle cell lymphoma. Cancer Res 70:1408-1418, 2010
44. Martin P, Chadburn A, Christos P, et al: Outcome of deferred initial therapy in mantle-cell lymphoma. J Clin Oncol 27:1209-1213, 2009
45. Leitch HA, Gascoyne RD, Chhanabhai M, et al: Limited-stage mantle-cell lymphoma. Ann Oncol 14: 1555-1561, 2003
46. Bernard M, Tsang RW, Le LW, et al: Limitedstage mantle cell lymphoma: Treatment outcomes at the Princess Margaret Hospital. Leuk Lymphoma 54: 261-267, 2013
47. Guru Murthy GS, Venkitachalam R, Mehta P: Effect of radiotherapy on the survival of patients with stage I and stage IImantle cell lymphoma: Analysis of the Surveillance, Epidemiology and End Results database. Clin Lymphoma Myeloma Leuk 14: S90-S95, 2014 (suppl)
48. Kluin-Nelemans HC, Hoster E, Hermine O, et al: Treatment of older patients with mantle-cell lymphoma. N Engl J Med 367:520-531, 2012
49. Delarue R, Haioun C, Ribrag V, et al: Groupe d'Etude des Lymphomes De l'Adulte (GELA): CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: A phase 2 study from the Groupe d'Etude des Lymphomes De l'Adulte. Blood 121:48-53, 2013
50. Geisler CH, Kolstad A, Laurell A, et al: Nordic Lymphoma Group: Long-term progression-free survival of mantle cell lymphoma after intensive frontline immunochemotherapy with in vivo-purged stem cell rescue: A nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 112: 2687-2693, 2008
51. Romaguera JE, Fayad L, Rodriguez MA, et al: High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 23:7013-7023, 2005
52. Hermine O, Hoster E, Walewski J, et al: Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high-dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP Plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: Results of the MCL Younger Trial of the European Mantle Cell Lymphoma Network (MCL net). Blood 116, 2010 (abstr 110)
53. Le Gouill S, Cartron G, Tournilhac O, et al: Rituximab maintenance versus WW after R-DHAP plus autologous stem cell transplantation in untreated patients with MCL: Interim analysis of the LYMA trial, a LYSA study. Hematol Oncol 33:131, 2015 (abstr)
54. Kolstad A, Laurell A, Jerkeman M, et al: Nordic Lymphoma Group: Nordic MCL3 study: 90Y-ibritumomab-tiuxetan added to BEAM/C in non-CR patients before transplant in mantle cell lymphoma. Blood 123:2953-2959, 2014
55. Bernstein SH, Epner E, Unger JM, et al: A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213. Ann Oncol 24: 1587-1593, 2013
56. Merli F, Luminari S, Ilariucci F, et al: Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 156:346-353, 2012
57. Arranz R, García-Noblejas A, Grande C, et al: First-line treatment with rituximab-hyperCVAD alternating with rituximab-methotrexate-cytarabine and followed by consolidation with 90Yibritumomab-tiuxetan in patients with mantle cell lymphoma. Results of a multicenter, phase 2 pilot trial from the GELTAMO group. Haematologica 98: 1563-1570, 2013
58. Geisler CH, Kolstad A, Laurell A, et al: Nordic Lymphoma Group: Nordic MCL2 trial update: Sixyear follow-up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC + autologous stem-cell support: Still very long survival but late relapses do occur. Br J Haematol 158:355-362, 2012
59. Romaguera JE, Fayad LE, Feng L, et al: Tenyear follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 150:200-208, 2010
60. Chihara D, Cheah CY, Westin JR, et al: Rituximabwith hyperCVADalternatingwithMTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15 year follow up of a phase II study fromMD Anderson Cancer Center. Br J Haematol doi: 10.1111/bjh.13796. [E-pub ahead of print]
61. LaCasce AS, Vandergrift JL, Rodriguez MA, et al: Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: An analysis from the NCCN NHL Database. Blood 119: 2093-2099, 2012
62. Ritchie DS, Seymour JF, Grigg AP, et al: The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ann Hematol 86:101-105, 2007
63. Chen R, Li H, Bernstein SH, et al: Results of a randomized phase II trial of R-HCVAD versus Rbendamustine followed by autologous stem cell transplantation for patients with mantle cell lymphoma: US Intergroup S1106. Hematol Oncol 33:132, 2015
64. Herbert KE, Ritchie DS, Seymour JF: Strategies to optimize collection of hematopoietic stem cells in patients with mantle cell lymphoma receiving hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone combined with cytarabine and methotrexate (Hyper-CVAD) chemotherapy. Leuk Lymphoma 52:935-937, 2011
65. Visco C, Finotto S, Zambello R, et al: Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol 31:1442-1449, 2013
66. Visco C, Chiappella A, Franceschetti S, et al: Rituximab, bendamustine and cytarabine (RBAC500) as induction therapy in elderly patients with mantle cell lymphoma: A phase II study from the Fondazione Italiana Linfomi. Hematol Oncol 33:130, 2015
67. Rummel MJ, Niederle N, Maschmeyer G, et al: Study group indolent Lymphomas (StiL): Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: An open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet 381:1203-1210, 2013
68. Flinn IW, Van Der Jagt R, Kahl BS, et al: Randomized trial of bendamustine-rituximab or RCHOP/R-CVP in first-line treatment of indolent NHL or MCL: The BRIGHT study. Blood 123:2944-2952, 2014
69. Smith MR, Li H, Gordon L, et al: Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499. J Clin Oncol 30: 3119-3126, 2012
70. Lenz G, Dreyling M, Hoster E, et al: Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: Results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 23:1984-1992, 2005
71. Robak T, Huang H, Jin J, et al: LYM-3002 Investigators: Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med 372: 944-953, 2015
72. Dietrich S, Weidle J, Rieger M, et al: Rituximab maintenance therapy after autologous stem cell transplantation prolongs progression-free survival in patients with mantle cell lymphoma. Leukemia 28: 708-709, 2014
73. Graf SA, Stevenson PA, Holmberg LA, et al: Rituximab maintenance therapy after autologous stem cell transplantation improves survival of patients with mantle cell lymphoma. Blood 124:3985, 2014 (abstr)
74. Till BG, Li H, Bernstein SH, et al: Phase II trial of R-CHOP plus bortezomib induction therapy followed by bortezomib maintenance for previously untreated mantle cell lymphoma: SWOG 0601. Blood 124:149, 2014 (abstr)
75. Schreiber S, Hoellein A, Decker T, et al: Everolimus maintenance in patients with mantle cell lymphoma not eligible for intensive therapy: Results of a prematurely closed phase 2 study. Leuk Lymphoma 10.3109/10428194.2015.1028055 [epub ahead of print on March 30, 2015
76. Rodríguez J, Gutierrez A, Palacios A, et al: Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma. Leuk Lymphoma 48: 2172-2178, 2007
77. Witzig TE, Geyer SM, Kurtin PJ, et al: North Central Cancer Treatment Group: Salvage chemotherapy with rituximab DHAP for relapsed non-Hodgkin lymphoma: A phase II trial in the North Central Cancer Treatment Group. Leuk Lymphoma 49:1074-1080, 2008
78. Wang M, Fayad L, Cabanillas F, et al: Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma. Cancer 113:2734-2741, 2008
79. Forstpointner R, Unterhalt M, Dreyling M, et al: German Low Grade Lymphoma Study Group (GLSG):Maintenance therapy with rituximab leads to a significant prolongation of response duration after salvage therapy with a combination of rituximab, fludarabine, cyclophosphamide, and mitoxantrone (R-FCM) in patients with recurring and refractory follicular and mantle cell lymphomas: Results of a prospective randomized study of the German Low Grade Lymphoma Study Group (GLSG). Blood 108: 4003-4008, 2006
80. Rummel MJ, Al-Batran SE, Kim SZ, et al: Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 23:3383-3389, 2005
81. Dietrich S, Boumendil A, Finel H, et al: Outcome and prognostic factors in patients with mantlecell lymphoma relapsing after autologous stem-cell transplantation: A retrospective study of the European Group for Blood and Marrow Transplantation (EBMT). Ann Oncol 25:1053-1058, 2014
82. Palanca-Wessels MC, Czuczman M, Salles G, et al: Safety and activity of the anti-CD79B antibodydrug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: A phase 1 study. Lancet Oncol 16:704-715, 2015
83. Davids MS, Seymour JF, Gerecitano JF, et al: Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. J Clin Oncol 32, 2014 (suppl; abstr 8522)
84. Wang ML, Rule S, Martin P, et al: Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 369:507-516, 2013
85. Kirschbaum M, Frankel P, Popplewell L, et al: Phase II study of vorinostat for treatment of relapsed or refractory indolent non-Hodgkin's lymphoma and mantle cell lymphoma. J Clin Oncol 29:1198-1203, 2011
86. Trneny M, Lamy T, Walewski J, et al: Phase II randomized, multicenter study of lenalidomide vs best investigator9s choice in relapsed/refractory mantle cell lymphoma: Results of the MCL-002 (SPRINT) study. Presented at the ASH Annual Meeting and Exposition, December 6-9, 2014 (abstr 626)
87. Zinzani PL, VoseJM, CzuczmanMS, et al: Longterm follow-up of lenalidomide in relapsed/refractory mantle cell lymphoma: Subset analysis of the NHL-003 study. Ann Oncol 24:2892-2897, 2013
88. Goy A, Sinha R, Williams ME, et al: Singleagent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: Phase II MCL-001 (EMERGE) study. J Clin Oncol 31:3688-3695, 2013
89. Hess G, Herbrecht R, Romaguera J, et al: Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 27:3822-3829, 2009
90. Renner C, Zinzani PL, Gressin R, et al: Swiss SAKK and French GOELAMS Group From European Mantle Cell Lymphoma Network: A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma. Haematologica 97: 1085-1091, 2012
91. Wang M, Popplewell LL, Collins RH, Jr, et al: Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: Multicentre, single-arm, phase 2 study. Br J Haematol 165: 510-518, 2014
92. Kahl BS, Spurgeon SE, Furman RR, et al: A phase 1 study of the PI3Kd inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL). Blood 123:3398-3405, 2014
93. Fisher RI, Bernstein SH, Kahl BS, et al: Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 24:4867-4874, 2006
94. Goy A, Bernstein SH, Kahl BS, et al: Bortezomib in patients with relapsed or refractory mantle cell lymphoma: Updated time-to-event analyses of the multicenter phase 2 PINNACLE study. Ann Oncol 20:520-525, 2009
95. Houot R, Le Gouill S, Ojeda Uribe M, et al: French GOELAMS Group: Combination of rituximab, bortezomib, doxorubicin, dexamethasone and chlorambucil (RiPAD+C) as first-line therapy for elderly mantle cell lymphoma patients: Results of a phase II trial from the GOELAMS. Ann Oncol 23: 1555-1561, 2012
96. Ruan J, Martin P, Furman RR, et al: Bortezomib plus CHOP-rituximab for previously untreated diffuse large B-cell lymphoma and mantle cell lymphoma. J Clin Oncol 29:690-697, 2011
97. Gressin R, Callanan M, Daguindau N, et al: Frontline therapy with the RiBVD regimen elicits high clinical and molecular response rates and long PFS in elderly patients mantle cell lymphoma (MCL); final results of a prospective phase II trial by the Lysa Group. Blood 124:2014 (abstr 148)
98. Romaguera JE, Fayad LE, McLaughlin P, et al: Phase I trial of bortezomib in combination with rituximab-hyperCVAD alternating with rituximab, methotrexate and cytarabine for untreated aggressive mantle cell lymphoma. Br J Haematol 151:47-53, 2010
99. Chang JE, Li H, Smith MR, et al: Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group study (E1405). Blood 123: 1665-1673, 2014
100. Maddocks K, Christian B, Jaglowski S, et al: A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. Blood 125: 242-248, 2015
101. Spurgeon S, Sharma K, Claxton DF, et al: Final results of a phase 1-2 study of vorinostat (SAHA), cladribine, and rituximab (SCR) relapsed B-cell non-Hodgkin's lymphoma and previously untreated mantle cell lymphoma. Blood 124, 2014 (abstr 1714)
102. Albertsson-Lindblad A, Kolstad A, Laurell A, et al: Lenalidomide-rituximab-bendamustine in first line for patients.65 with mantle cell lymphoma: Final results of the Nordic Lymphoma Group MCL4 (LENABERIT) phase I/II trial. Hematol Oncol 33:131, 2015
103. Chang JE, Peterson C, Choi S, et al: VcR-CVAD induction chemotherapy followed by maintenance rituximab in mantle cell lymphoma: A Wisconsin Oncology Network study. Br J Haematol 155: 190-197, 2011
104. Hipp S, Ringshausen I, Oelsner M, et al: Inhibition of the mammalian target of rapamycin and the induction of cell cycle arrest in mantle cell lymphoma cells. Haematologica 90:1433-1434, 2005
105. Witzig TE, Geyer SM, Ghobrial I, et al: Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23: 5347-5356, 2005
106. Ansell SM, Inwards DJ, Rowland KM Jr, et al: Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: A phase 2 trial in the North Central Cancer Treatment Group. Cancer 113: 508-514, 2008
107. Qian Z, Zhang L, Cai Z, et al: Lenalidomide synergizes with dexamethasone to induce growth arrest and apoptosis of mantle cell lymphoma cells in vitro and in vivo. Leuk Res 35:380-386, 2011
108. Desai M, Newberry K, Ou Z, et al: Lenalidomide in relapsed or refractory mantle cell lymphoma: Overview and perspective. Ther Adv Hematol 5: 91-101, 2014
109. Song K, Herzog BH, Sheng M, et al: Lenalidomide inhibits lymphangiogenesis in preclinical models of mantle cell lymphoma. Cancer Res 73: 7254-7264, 2013
110. Moros A, Rodríguez V, Saborit-Villarroya I, et al: Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma. Leukemia 28:2049-2059, 2014
111. Habermann TM, Lossos IS, Justice G, et al: Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma. Br J Haematol 145:344-349, 2009
112. Witzig TE, Vose JM, Zinzani PL, et al: An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 22:1622-1627, 2011
113. Wang M, Fayad L, Wagner-Bartak N, et al: Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: A phase 1/2 clinical trial. Lancet Oncol 13: 716-723, 2012
114. Ruan J, Martin P, Shah BD, et al: Lenalidomide plus rituximab as initial treatment for mantle-cell lymphoma. N Engl J Med 373:1835-1844, 2015
115. Honigberg LA, Smith AM, Sirisawad M, et al: The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy. Proc Natl Acad Sci U S A 107:13075-13080, 2010
116. Ponader S, Chen SS, Buggy JJ, et al: The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. Blood 119:1182-1189, 2012
117. Advani RH, Buggy JJ, Sharman JP, et al: Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. J Clin Oncol 31: 88-94, 2013
118. Wang MK, Lee H, Chuang H, et al: Ibrutinib in combination with rituximab in relapsed or refractory mantle cell lymphoma: Results from a single-center, open label phase 2 trial. Lancet Oncol doi: 10.1016/S1470-2045(15)00438-6. [E-pub ahead of print]
119. Cheah CY, Chihara D, Romaguera JE, et al: Patients with mantle cell lymphoma failing ibrutinib are unlikely to respond to salvage chemotherapy and have poor outcomes. Ann Oncol 26:1175-1179, 2015
120. Younes A, Thieblemont C, Morschhauser F, et al: Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: A nonrandomised, phase 1b study. Lancet Oncol 15: 1019-1026, 2014
121. Furtado M, Dyer MJS, Johnson R, et al: Ofatumumab monotherapy in relapsed/refractory mantle cell lymphoma-a phase II trial. Br J Haematol 165:575-578, 2014
122. Morschhauser FA, Cartron G, Thieblemont C, et al: Obinutuzumab (GA101)monotherapy in relapsed/refractory diffuse large b-cell lymphoma or mantle-cell lymphoma: Results from the phase II GAUGUIN study. J Clin Oncol 31:2912-2919, 2013
123. Heider U, Kaiser M, Sterz J, et al: Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur J Haematol 76:42-50, 2006
124. Watanabe T, Kato H, Kobayashi Y, et al: Potential efficacy of the oral histone deacetylase inhibitor vorinostat in a phase I trial in follicular and mantle cell lymphoma. Cancer Sci 101:196-200, 2010
125. Evens AM, Vose JM, Harb W, et al: A phase II multicenter study of the histone deacetylase inhibitor (HDACi) abexinostat (PCI-24781) in relapsed/refractory follicular lymphoma (FL) and mantle cell lymphoma (MCL). Blood 120, 2012 (abstr 55)
126. Inwards DJ, Fishkin PA, Hillman DW, et al: Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment Group. Cancer 113: 108-116, 2008
127. Rizzatti EG, Falcão RP, Panepucci RA, et al: Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K-AKT, WNT and TGFbeta signalling pathways. Br J Haematol 130:516-526, 2005
128. Meadows SA, Vega F, Kashishian A, et al: PI3Kd inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119: 1897-1900, 2012
129. Lannutti BJ, Meadows SA, Herman SE, et al: CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability. Blood 117:591-594, 2011
130. Horwitz SM, Flinn I, Patel MR, et al: Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-d,g, in patients with relapsed/refractory lymphoma. J Clin Oncol 31, 2013 (suppl; abstr 8518)
131. Leonard JP, LaCasce AS, Smith MR, et al: Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119:4597-4607, 2012
132. Morschhauser F, Bouabdallah K, Stilgenbauer S, et al: Clinical activity of abemaciclib (LY2835219), a cell cycle inhibitor selective for CDK4 and CDK6, in Patients with relapsed or refractory mantle cell lymphoma. Blood 124, 2014 (abstr 3067)
133. Roberts AW, Seymour JF, Brown JR, et al: Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: Results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488-496, 2012
134. Souers AJ, Leverson JD, Boghaert ER, et al: ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19:202-208, 2013
135. Kochenderfer JN, Feldman SA, Zhao Y, et al: Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J Immunother 32: 689-702, 2009
136. Porter DL, Levine BL, Kalos M, et al: Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365:725-733, 2011
137. Maude SL, Frey N, Shaw PA, et al: Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371:1507-1517, 2014
138. Kochenderfer JN, Dudley ME, Kassim SH, et al: Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell Malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 33:540-549, 2014
139. Schuster SJ, Svoboda J, Dwivedy Nasta S, et al: Phase IIa trial of chimeric antigen receptor modified T cells directed against CD19 (CTL019) in patients with relapsed or refractory CD19+ lymphomas, 2014
140. Plesner T, Arkenau H-T, Lokhorst HM, et al: Safety and efficacy of daratumumab with lenalidomide and dexamethasone in relapsed or relapsed, refractory multiple myeloma. Blood 124, 2014 (abstr84)
141. De Weers M, Tai YT, Van Der Veer MS, et al: Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186:1840-1848, 2011
142. Deckert J, Wetzel MC, Bartle LM, et al: SAR650984, a novel humanized CD38-targeting antibody, demonstrates potent antitumor activity in models of multiple myeloma and other CD38+ hematologic malignancies. Clin Cancer Res 20: 4574-4583, 2014
143. Ansell SM, Tang H, Kurtin PJ, et al: Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: A PHASE 2 study. Lancet Oncol 12:361-368, 2011